Secondary analysis of RxPONDER (HR+/HER2− node-positive, RS ≤25, age <55; n=1556): chemo plus endocrine therapy improved IDFS only with AMH ≥10 pg/ml (HR 0.46); no benefit with AMH <10 pg/ml (HR 1.27, non-significant).
Secondary analysisn = 1,556
Kalinsky et al. Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)